Biogen (BIIB) has generated significant attention with its developments in Alzheimer’s treatment, securing EU approval for its drug
Leqembi in 48 countries and FDA acceptance for their Investigational New Drug,
BIIB-142. The company's groundbreaking
Alzheimer’s therapy and Dravet Data contributed to a 6.4% increase in their stock. However, insider selling has taken place with notable Biogen staff selling portions of their shares. Despite some stock trades fluctuating downwards, several new investments in Biogen were made from entities such as
Evergreen Capital Management LLC and
Landscape Capital Management L.L.C. Furthermore, regulatory approval for
subcutaneous maintenance dosing of Leqembi has been achieved and the potential for Biogen's Zorevunersen as a first disease-modifying drug for Dravet Syndrome, demonstrated with an 84.8% seizure reduction. Amidst the advancements, the company is also looking at a possible bid for the merger with
Sage Therapeutics.
Biogen BIIB News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sat, 06 Sep 2025 23:51:49 GMT -
Rating 7
- Innovation 5
- Information 6
- Rumor -4
